Hosted on MSN1mon
Immuneering and Regeneron partner on lung cancer trial
The company's pipeline includes IMM-6-415, another deep cyclic inhibitor of MEK, which is also undergoing a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations.
Business Insider1mon
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
IMM-6-415 is an oral, twice-daily deep cyclic inhibitor of MEK currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. The company’s development ...